The United States Food and Drug Administration (FDA) has approved rapamycin (sirolimus) and several rapamycin derivative compounds (“rapalogs”) that inhibit mTOR for the treatment of renal cancer, subependymal giant cell astrocytoma associated with tuberous sclerosis, and neuroendocrine pancreatic tumors. Here, MTOR is linked to tuberous sclerosis.